# Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT03017131** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Decitabine
- **BIOLOGICAL:** Genetically Engineered NY-ESO-1-specific T Lymphocytes
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03017131
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-08
- **Primary completion:** 2020-03-23
- **Final completion:** 2032-03-23
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03017131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03017131, "Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03017131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*